Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells
Diego Martín‐Sánchez, Ángel Gallegos-Villalobos, Miguel Fontecha‐Barriuso, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

The multifaceted role of iron in renal health and disease
Rachel P. L. van Swelm, Jack F.M. Wetzels, Dorine W. Swinkels
Nature Reviews Nephrology (2019) Vol. 16, Iss. 2, pp. 77-98
Closed Access | Times Cited: 234
M. tuberculosis Reprograms Hematopoietic Stem Cells to Limit Myelopoiesis and Impair Trained Immunity
Nargis Khan, Jeffrey Downey, Joaquín Sanz, et al.
Cell (2020) Vol. 183, Iss. 3, pp. 752-770.e22
Open Access | Times Cited: 200
Regulated cell death pathways in kidney disease
Ana B. Sanz, María Dolores Sánchez-Niño, Adrián M. Ramos, et al.
Nature Reviews Nephrology (2023) Vol. 19, Iss. 5, pp. 281-299
Open Access | Times Cited: 158
Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors
Camilla Scarpellini, Greta Klejborowska, Caroline Lanthier, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 12, pp. 902-916
Open Access | Times Cited: 73
Ferroptosis and kidney disease
Diego Martín‐Sánchez, Miguel Fontecha‐Barriuso, Julio M. Martínez‐Moreno, et al.
Nefrología (2020) Vol. 40, Iss. 4, pp. 384-394
Open Access | Times Cited: 69
Molecular pathways driving omeprazole nephrotoxicity
Miguel Fontecha‐Barriuso, Diego Martín‐Sánchez, Julio M. Martínez‐Moreno, et al.
Redox Biology (2020) Vol. 32, pp. 101464-101464
Open Access | Times Cited: 52
Natural flavonoids from herbs and nutraceuticals as ferroptosis inhibitors in central nervous system diseases: current preclinical evidence and future perspectives
Qiuhe Li, Xiaohang Yang, Tiegang Li
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields
Diego Martín‐Sánchez, Miguel Fontecha‐Barriuso, María Dolores Sánchez-Niño, et al.
Cell Death and Disease (2018) Vol. 9, Iss. 2
Open Access | Times Cited: 32
Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study
Hamidreza Badeli, Adel Baghersalimi, Sajjad Eslami, et al.
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-8
Open Access | Times Cited: 31
Effective synthesis of fluorescent carbon dots and their application in controllable detection of deferasirox
Yao Wang, Gengping Pan, Chenfang Miao, et al.
Microchemical Journal (2024) Vol. 206, pp. 111536-111536
Closed Access | Times Cited: 3
The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability
Esther Maria Gottwald, Claus D. Schuh, Patrick Drücker, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 27
Ferroptosis and kidney disease
Diego Martín‐Sánchez, Miguel Fontecha‐Barriuso, Julio M. Martínez‐Moreno, et al.
Nefrología (English Edition) (2020) Vol. 40, Iss. 4, pp. 384-394
Open Access | Times Cited: 22
Assessment of Subclinical Renal Glomerular and Tubular Dysfunction in Children with Beta Thalassemia Major
Asmaa A. Mahmoud, Doaa M. Elian, Nahla MS. Abd El Hady, et al.
Children (2021) Vol. 8, Iss. 2, pp. 100-100
Open Access | Times Cited: 19
Bibliometric analysis of ferroptosis in acute kidney injury from 2014 to 2022
Chao Liu, Wuhong Zhou, Zhi Mao, et al.
International Urology and Nephrology (2023) Vol. 55, Iss. 6, pp. 1509-1521
Closed Access | Times Cited: 7
Fabrication of deferasirox-decorated aptamer-targeted superparamagnetic iron oxide nanoparticles (SPION) as a therapeutic and magnetic resonance imaging agent in cancer therapy
Seyed Mojtaba Mashmoul Moghadam, Mona Alibolandi, Maryam Babaei, et al.
JBIC Journal of Biological Inorganic Chemistry (2020) Vol. 26, Iss. 1, pp. 29-41
Closed Access | Times Cited: 20
Renal function in β-thalassemia major patients treated with two different iron-chelation regimes
Osama Tanous, Yossi Azulay, Raphaël Halevy, et al.
BMC Nephrology (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Measurement of the liver iron concentration in transfusional iron overload by MRI R2* and by high-transition-temperature superconducting magnetic susceptometry
Sujit Sheth, Christopher Allen, David E. Farrell, et al.
Clinical Imaging (2019) Vol. 55, pp. 65-70
Open Access | Times Cited: 14
Kidney tubule iron loading in experimental focal segmental glomerulosclerosis
Rachel P. L. van Swelm, Sanne Beurskens, Henry Dijkman, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Deferasirox’s Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma
Yamixa Delgado, Anamaris Torres-Sanchez, Daraishka Pérez, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2272-2272
Open Access | Times Cited: 1
Subclinical nephrotoxicity in patients with beta-thalassemia: role of urinary kidney injury molecule
Ola Elsayed Nafea, Marwa Zakaria, Tamer Hassan, et al.
Drug and Chemical Toxicology (2019) Vol. 45, Iss. 1, pp. 93-102
Closed Access | Times Cited: 10
Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo
Nan Zhou, Yan Cui, Rui Zhu, et al.
Gynecologic Oncology (2022) Vol. 166, Iss. 1, pp. 126-137
Open Access | Times Cited: 6
Deferasirox and vitamin D3 co-therapy mitigates iron-induced renal injury by enhanced modulation of cellular anti-inflammatory, anti-oxidative stress, and iron regulatory pathways in rat
Mazen M. Ghaith, Mohamed El‐Boshy, Hussain A. Almasmoum, et al.
Journal of Trace Elements in Medicine and Biology (2022) Vol. 74, pp. 127085-127085
Closed Access | Times Cited: 6
The iron chelator deferriferrichrysin induces paraptosis via extracellular signal‐related kinase activation in cancer cells
Natsuki Kinoshita, Masaya Gessho, Takeru Torii, et al.
Genes to Cells (2023) Vol. 28, Iss. 9, pp. 653-662
Closed Access | Times Cited: 3
ATF4-activated parkin induction contributes to deferasirox-mediated cytoprotection in Parkinson’s disease
Sangwoo Ham, Ji Hun Kim, Heejeong Kim, et al.
Toxicological Research (2022) Vol. 39, Iss. 2, pp. 191-199
Open Access | Times Cited: 4
Nephrotoxicity
Ana B. Sanz, María Dolores Sánchez-Niño, Adrián M. Ramos, et al.
(2018), pp. 169-184
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top